Clinical trials: Demyelinating Disorder
Multiple Sclerosis, Relapsing-Remitting, Relapsing-Remitting Multiple Sclerosis
Effectiveness of DMF (Dimethyl Fumarate) and Its Impact on PROs (Patient Reported Outcomes) in Treatment-Naive or Suboptimal IFN (Interferon) or GA (Glatiramer Acetate) Responders With RRMS (ImPROve)
The primary objective of the study is to estimate the annualized relapse rate (ARR) over a 12-month period in patients with Relapsing-Remitting Multiple Sclerosis (RRMS) who are treated with dimethyl fumarate (DMF) as their…
- Trial name
- IMPROVE (NCT02323269)
- Testing
- dimethyl fumarate
- Where
- 10 sites in Canada
- Volunteers
- 24 people
- Sponsor
- Biogen
Multiple Sclerosis, Relapsing-Remitting
COMPliance With Avonex® PS in Patients With Relapsing-Remitting MS
A phase IV, observational, survey-based study to measure compliance with Avonex® PS therapy in patients with Relapsing-Remitting Multiple Sclerosis, and to compare persistence on therapy 22 months after initial prescription of…
- Trial name
- COMPASS (NCT00675883)
- Where
- Canada
- Volunteers
- 1,000 people
- Sponsor
- Biogen
Bladder Dysfunction, Multiple Sclerosis
Efficacy of Clean Intermittent Catheterization (CIC) in Multiple Sclerosis (MS) Patients With Bladder Dysfunction
The aims of this prospective, randomized study are: To assess the effect of clean intermittent catheterization (CIC) To investigate if MS patients will have symptom reduction (urgency, frequency, nocturia and incontinence) when…
- Trial name
- NCT00913510
- Testing
- CIC using LoFric Primo, Anticholinergic medication
- Where
- 5 sites in Belgium, Germany and 2 more
- Volunteers
- 24 people
- Sponsor
- Wellspect HealthCare
Restless Legs Syndrome, Multiple Sclerosis
Hypnosis and Direct Autonomic Experience Influence on Chronic Symptoms
Study will look at a limited number of participants with various chronic symptoms. Investigating a new and novel form of hypnosis application called "Direct Autonomic Experience (DAX)" which is using combination of visualization…
- Conditions
- Restless Legs Syndrome, Multiple Sclerosis, Trauma, Psychological, Chronic Disease
- Trial name
- HDAX1 (NCT04303143)
- Testing
- Self-Hypnosis, Direct Autonomic Experience Control
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Inner Group Inc.
Multiple Sclerosis, Primary Progressive Multiple Sclerosis (PPMS)
IDP-023 g-NK Cells Plus Ocrelizumab in Patients With Progressive Multiple Sclerosis
This is an open label, Phase 1b, multiple ascending dose, and dose-expansion study of IDP-023 administered in combination with interleukin-2 (IL-2) and ocrelizumab to evaluate the safety, tolerability, and biologic activity on…
- Conditions
- Multiple Sclerosis, Primary Progressive Multiple Sclerosis (PPMS), Secondary Progressive Multiple Sclerosis (SPMS), Non-Active Secondary Progressive Multiple Sclerosis
- Trial name
- NCT06677710
- Testing
- IDP-023, Ocrelizumab, Interleukin-2
- Where
- 5 sites in United States
- Volunteers
- 34 people
- Sponsor
- Indapta Therapeutics, INC.
Relapsing Multiple Sclerosis
Safety and Effectiveness of Cinnomer® (Glatiramer Acetate) in Multiple Sclerosis (MS) Treatment in Iran
This trial was an obsevational phase IV prospective multicenter study designed to evaluate the safety and effectiveness of Cinnomer® in patients with MS in Iran.
- Trial name
- NCT04928313
- Testing
- Glatiramer Acetate
- Volunteers
- 368 people
- Sponsor
- Cinnagen
Secondary Progressive Multiple Sclerosis
AIMSPRO in the Treatment of Bladder Dysfunction in Secondary Progressive Multiple Sclerosis
Patients with marked bladder dysfunction as a result of secondary progressive multiple sclerosis are being recruited to receive AIMSPRO or placebo by subcutaneous injection, in this double-blind crossover study.
- Trial name
- NCT01228396
- Testing
- Hyperimmune caprine serum against HIV lysate
- Where
- United Kingdom
- Volunteers
- 20 people
- Sponsor
- Daval International Limited
Optic Neuritis, Optic; Neuritis, With Demyelination
BN201 SAD MAD Study in Healthy Subjects
The purpose of this study is to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple doses of BN201 in healthy subjects.
- Trial name
- NCT03630497
- Where
- United Kingdom
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Accure Therapeutics
Relapsing-Remitting Multiple Sclerosis
Glatiramer Acetate (Copaxone®) Study to Follow Participants From the First Original Study for Safety and Effectiveness
This open-label extension study will evaluate the long-term safety of glatiramer acetate and its effect on the neurologic course of participants with relapsing-remitting multiple sclerosis (RRMS).
- Trial name
- NCT00203021
- Testing
- Glatiramer acetate
- Where
- 11 sites in United States
- Volunteers
- 208 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Multiple Sclerosis, Relapsing
Prospective Study to Assess Disease Activity and Biomarkers in Minority Participants With Relapsing Multiple Sclerosis (RMS) After Initiation and During Treatment With Ocrelizumab
Open-label, prospective, single-arm, multi-center study to assess disease activity and biomarker of neuronal damage in minority patients (self-identified Black or African American (AA) and Hispanic/Latino (HA) patients with…
- Trial name
- NCT04377555
- Testing
- Ocrelizumab
- Where
- 28 sites in United States, Kenya and 1 more
- Volunteers
- 179 people
- Sponsor
- Genentech, Inc.
Multiple Sclerosis, Relapsing-Remitting
A Phase IIIb, Multicenter, International Study to Evaluate the Efficacy, Safety and Tolerability of EK-12 in Patients With RRMS
Multiple sclerosis is a chronic autoimmune, inflammatory neurological disease of the central nervous system. It is the most common disabling neurologic disease of young people.
- Trial name
- NCT03283397
- Testing
- EK-12, INF beta-1a
- Where
- Turkey (Türkiye)
- Volunteers
- 301 people
- Sponsor
- Bosnalijek D.D
Multiple Sclerosis
Multiple Sclerosis Patient Experience on Kesimpta and Ocrevus Subcutaneous Formulation
The study aimed to compare the experiences, including injection-related reactions (IRRs) of patients newly receiving ofatumumab to those starting to receive ocrelizumab SC formulation.
- Trial name
- MS-PEKOS (NCT06668324)
- Where
- United States
- Volunteers
- 134 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Inflammatory Demyelinating Polyneuropathy
A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE)
The purpose of this Phase 3 study is to demonstrate the efficacy of claseprubart (DNTH103) as compared to placebo in participants with chronic inflammatory demyelinating polyneuropathy (CIDP).
- Trial name
- CAPTIVATE (NCT06858579)
- Testing
- Claseprubart
- Where
- 201 sites in United States, Argentina and 29 more
- Volunteers
- 256 people
- Sponsor
- Dianthus Therapeutics
Multiple Sclerosis
Patient Satisfaction Study of Single-Use Autoinjector for the Delivery of Pre-Filled Avonex Syringe
Determine patient satisfaction with the single-use autoinjector for the delivery of pre-filled Avonex syringe.
- Trial name
- NCT00915577
- Testing
- Interferon beta-1a, Single-use autoinjector
- Volunteers
- 74 people
- Sponsor
- Biogen
Multiple Sclerosis, Relapsing-Remitting
Assessment of Repeat Ascending Doses of GSK2018682 in Healthy Volunteers
The study will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of repeat ascending doses of GSK2018682.
- Trial name
- P1A114347 (NCT01431937)
- Testing
- GSK2018682
- Where
- 3 sites in Australia
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Relapsing Remitting Multiple Sclerosis
A Study to Evaluate the Long Term Safety and Effectiveness of Novantrone Therapy Followed by Copaxone Treatment for Multiple Sclerosis
It is thought that treating Multiple Sclerosis with Novantrone for a short period of time prior to treatment with Copaxone may enhance the onset effect of Copaxone.
- Trial name
- NCT00203086
- Volunteers
- 30 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Mitochondrial Diseases, Drug Resistant Epilepsy
A Study to Evaluate Efficacy and Safety of Vatiquinone for Treating Mitochondrial Disease in Participants With Refractory Epilepsy
This is a parallel-arm, double-blind, placebo-controlled study with a screening phase that includes a 28-day run-in phase to establish baseline seizure frequency, followed by a 24-week, randomized, placebo-controlled phase.
- Conditions
- Mitochondrial Diseases, Drug Resistant Epilepsy, Leigh Disease, Leigh Syndrome
- Trial name
- MIT-E (NCT04378075)
- Testing
- Vatiquinone
- Where
- 27 sites in United States, Canada and 7 more
- Volunteers
- 68 people
- Sponsor
- PTC Therapeutics
Multiple Sclerosis, Relapsing-Remitting
A Study to Assess New Participant's Perspectives Beyond Clinical Efficacy of Monoclonal Antibody-Based Relapsing Remitting Multiple Sclerosis (RRMS) Treatments
The primary objective of the study is to understand what the added value of natalizumab (Tysabri®) treatment is from a participant's perspective at a given time, based on a one-shot survey.
- Trial name
- NCT06127095
- Where
- United States
- Volunteers
- 474 people
- Sponsor
- Biogen
Multiple Sclerosis
Exploratory Study to Assess the Effect of Fampridine (BIIB041) on Walking Ability and Balance in Participants With Multiple Sclerosis.
The objectives of this study in Multiple Sclerosis (MS) participants treated with prolonged-released fampridine (BIIB041) 10 mg twice daily compared with participants treated with placebo are to assess the effect over 24 weeks on…
- Trial name
- MOBILE (NCT01597297)
- Testing
- BIIB041 (PR Fampridine)
- Where
- 23 sites in Belgium, Canada and 4 more
- Volunteers
- 132 people
- Sponsor
- Biogen
Relapsing Remitting Multiple Sclerosis
Proof of Concept Study Evaluating RNS60 in the Treatment of Relapsing Remitting Multiple Sclerosis
The purpose of this study is to determine whether RNS60 is effective in the treatment of RR-MS compared to interferon beta-1a.
- Trial name
- NCT01714089
- Testing
- RNS60 125 ml, RNS60 250 ml, Interferon beta 1a
- Where
- United States
- Sponsor
- Revalesio Corporation
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.